ArticleDigestive diseases and sciences2025
Endoscopic Submucosal Dissection for Recurrent Esophageal Squamous Cell Carcinoma Post-Radiation.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe feasibility and outcomes of salvage endoscopic submucosal dissection (ESD) and ESD for metachronous esophageal squamous cell cancer (ESCC) inside the irradiated field are not clear.
aimsTo explore the viability of ESD for ESCC in areas previously exposed to radiation, identify elements hindering successful ESD, assess prognosis, and elucidate considerations for follow-up.
methodsPatients with ESCC who underwent salvage ESD or ESD for metachronous ESCC within the previously irradiated field at Kanagawa Cancer Center between January 1, 2013, and December 31, 2023, were retrospectively investigated to evaluate patient and lesion characteristics and short- and long-term outcomes.
resultsThirty patients with 41 lesions were analyzed. The median age was 73 (52-88), and 93.3% were men. The middle thorax was the primary location, with flat lesions constituting 73.2%. In salvage ESD cases, the en bloc dissection rate was 91.3%, without adverse events. Conversely, the en bloc dissection rate in metachronous ESD was 100%, and aspiration pneumonitis and post-procedure stricture occurred in 12.5% and 12.5%, respectively. No lesion removed by salvage ESD recurred. During a median follow-up period of 685 (range 24-3061) days, 10 patients (52.6%) developed other organ malignancies, three died from pneumonia, and one died from pharyngeal cancer. The 5-year overall survival rate was 74.9%. No patient died of esophageal cancer.
conclusionsSalvage and metachronous ESD are feasible and can achieve high en bloc resection rates and good local control. Screening for other organ malignancies after salvage ESD is indispensable. Preventing aspiration may also improve the prognosis.
Indexed as
Identifiers
39694992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.